Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash from Financing Activities (2016 - 2025)

IGC Pharma (IGC) has disclosed Cash from Financing Activities for 16 consecutive years, with $3.1 million as the latest value for Q3 2025.

  • Quarterly Cash from Financing Activities rose 291.69% to $3.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Sep 2025, up 28.84% year-over-year, with the annual reading at $4.5 million for FY2025, 26.31% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was $3.1 million at IGC Pharma, up from $851000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $14.2 million in Q1 2021, with the low at -$1000.0 in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $1.7 million, with a median of $696500.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities crashed 100.14% in 2022, then surged 250800.0% in 2024.
  • Over 5 years, Cash from Financing Activities stood at -$1000.0 in 2021, then soared by 10300.0% to $102000.0 in 2022, then plummeted by 100.98% to -$1000.0 in 2023, then skyrocketed by 34600.0% to $345000.0 in 2024, then surged by 801.45% to $3.1 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $3.1 million, $851000.0, and $805000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.